Atalaya Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Atalaya Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$8.5K	Sell	424,867 -133	-0%	-$8	0.02%	51
2024 Q1	$37.8K	Buy	425,000 +200,000	+89%	+$12.2K	0.04%	38
2023 Q4	$4.5K	Hold	225,000	–	–	0.01%	82
2023 Q3	$15.8K	Hold	225,000	–	–	0.02%	74
2023 Q2	$13.5K	Hold	225,000	–	–	0.01%	102
2023 Q1	$9K	Hold	225,000	–	–	﹤0.01%	159
2022 Q4	$9K	Hold	225,000	–	–	﹤0.01%	192
2022 Q3	$18K	Hold	225,000	–	–	﹤0.01%	244
2022 Q2	$25K	Hold	225,000	–	–	﹤0.01%	238
2022 Q1	$50K	Hold	225,000	–	–	0.01%	277
2021 Q4	$95K	Buy	+225,000	New	+$104K	0.01%	283

Other funds holding CEROW

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

CSD

Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Atalaya Capital Management's CEROW Position: Q2 2024 in Review

Atalaya Capital Management reduced its CERo Therapeutics Warrants (CEROW) stake by 0.03% in Q2 2024, selling an estimated $8 and leaving 424,867 shares worth $8.5K. The position accounts for 0.02% of the portfolio, ranked #51.

Atalaya Capital Management first reported a position in CEROW in Q4 2021 and has held it in 11 quarters since. The position peaked at $95K in Q4 2021. 34 funds tracked by Wall St. Rank hold CEROW as of Q2 2024.

Atalaya Capital Management held 424,867 shares of CERo Therapeutics Warrants worth $8.5K as of Q2 2024.
Atalaya Capital Management sold 133 CERo Therapeutics Warrants shares in Q2 2024, an estimated $8.
CERo Therapeutics Warrants made up 0.02% of Atalaya Capital Management's portfolio in Q2 2024, its #51 holding.
Atalaya Capital Management first reported a position in CERo Therapeutics Warrants in Q4 2021 and has held it in 11 quarters since.
Atalaya Capital Management's CERo Therapeutics Warrants position peaked at $95K in Q4 2021.
34 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2024.

Based on Atalaya Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.